Literature DB >> 21909080

CXCR4 expression correlates with the degree of tumor infiltration and BRAF status in papillary thyroid carcinomas.

Liborio Torregrossa1, Riccardo Giannini, Nicla Borrelli, Elisa Sensi, Rosa Marina Melillo, Pietro Leocata, Gabriele Materazzi, Paolo Miccoli, Massimo Santoro, Fulvio Basolo.   

Abstract

Emerging evidence indicates that interactions between chemokine receptors and their ligands may have a critical role in several steps of tumor development, including tumor growth, progression, and metastasis. In this report, we retrospectively evaluated CXCR4 expression in a consecutive series of 200 papillary thyroid carcinomas. We investigated the relationship between the clinicopathological features of the tumors and mutations in the BRAF gene to verify whether overexpression of CXCR4 is linked to more aggressive behavior in thyroid tumors. CXCR4 protein expression was evaluated by immunohistochemical staining. A final staining score was calculated by adding the score representing the percentage of positive cells to the intensity score. The CXCR4 expression of each papillary thyroid carcinoma sample was normalized by calculating the z score for each final staining score. Univariate analysis was used to correlate CXCR4 expression with the papillary thyroid carcinoma variant, the degree of neoplastic infiltration, the American Joint Commission on Cancer stage, the presence of lymphocytic thyroiditis and the mutation status of the BRAF gene. Multiple regression analysis confirmed a strong association between CXCR4, BRAF mutation and the degree of neoplastic infiltration. These data clearly indicate that the chemokine receptor expression induced by oncogenic activation could be the major determinant of the local aggressiveness of neoplastic cells. In conclusion, our data indicate that CXCR4 expression and BRAF mutation status could cooperatively induce and promote a more aggressive phenotype in papillary thyroid carcinoma through several pathways and specifically increase the tumors' spread outside of the thyroid gland.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21909080     DOI: 10.1038/modpathol.2011.140

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  14 in total

1.  Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma.

Authors:  Nicolas Jacquelot; David P Enot; Caroline Flament; Nadège Vimond; Carolin Blattner; Jonathan M Pitt; Takahiro Yamazaki; María Paula Roberti; Romain Daillère; Marie Vétizou; Vichnou Poirier-Colame; Michaëla Semeraro; Anne Caignard; Craig L Slingluff; Federica Sallusto; Sylvie Rusakiewicz; Benjamin Weide; Aurélien Marabelle; Holbrook Kohrt; Stéphane Dalle; Andréa Cavalcanti; Guido Kroemer; Anna Maria Di Giacomo; Michele Maio; Phillip Wong; Jianda Yuan; Jedd Wolchok; Viktor Umansky; Alexander Eggermont; Laurence Zitvogel
Journal:  J Clin Invest       Date:  2016-02-08       Impact factor: 14.808

2.  Expression of CXCL12 and its receptor CXCR4 in patients with adenomyosis.

Authors:  Juan Li; Geping Yin; Ming Chen; Shujun Yang; Aifang Wu; Jing Liang; Zheng Yuan
Journal:  Oncol Lett       Date:  2017-02-22       Impact factor: 2.967

3.  Comparative evaluation of somatostatin and CXCR4 receptor expression in different types of thyroid carcinoma using well-characterised monoclonal antibodies.

Authors:  Max Czajkowski; Daniel Kaemmerer; Jörg Sänger; Guido Sauter; Ralph M Wirtz; Stefan Schulz; Amelie Lupp
Journal:  BMC Cancer       Date:  2022-07-07       Impact factor: 4.638

4.  RNA sequencing identifies multiple fusion transcripts, differentially expressed genes, and reduced expression of immune function genes in BRAF (V600E) mutant vs BRAF wild-type papillary thyroid carcinoma.

Authors:  Robert C Smallridge; Ana-Maria Chindris; Yan W Asmann; John D Casler; Daniel J Serie; Honey V Reddi; Kendall W Cradic; Michael Rivera; Stefan K Grebe; Brian M Necela; Norman L Eberhardt; Jennifer M Carr; Bryan McIver; John A Copland; E Aubrey Thompson
Journal:  J Clin Endocrinol Metab       Date:  2013-12-02       Impact factor: 5.958

5.  CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy.

Authors:  S Matsusaka; S Cao; D L Hanna; Y Sunakawa; M Ueno; N Mizunuma; W Zhang; D Yang; Y Ning; S Stintzing; A Sebio; S Stremitzer; S Yamauchi; A Parekh; S Okazaki; M D Berger; R El-Khoueiry; A Mendez; W Ichikawa; F Loupakis; H-J Lenz
Journal:  Pharmacogenomics J       Date:  2016-08-09       Impact factor: 3.550

6.  Mouse models of follicular and papillary thyroid cancer progression.

Authors:  Marika A Russo; Valeria G Antico Arciuch; Antonio Di Cristofano
Journal:  Front Endocrinol (Lausanne)       Date:  2012-01-10       Impact factor: 5.555

7.  Effects of Astragaloside IV on the SDF-1/CXCR4 Expression in Atherosclerosis of apoE(-/-) Mice Induced by Hyperlipaemia.

Authors:  Hewei Qin; Ping Liu; Shengchao Lin
Journal:  Evid Based Complement Alternat Med       Date:  2015-05-17       Impact factor: 2.629

8.  Molecular pathways associated with aggressiveness of papillary thyroid cancer.

Authors:  Salvatore Benvenga; Christian A Koch
Journal:  Curr Genomics       Date:  2014-06       Impact factor: 2.236

9.  Quercetin inhibits NTHi-triggered CXCR4 activation through suppressing IKKα/NF-κB and MAPK signaling pathways in otitis media.

Authors:  Yu-Kun Ma; Yu-Bin Chen; Peng Li
Journal:  Int J Mol Med       Date:  2018-03-20       Impact factor: 4.101

10.  Effect of CXCL12/CXCR4 on increasing the metastatic potential of non-small cell lung cancer in vitro is inhibited through the downregulation of CXCR4 chemokine receptor expression.

Authors:  Songping Xie; Wenhui Zeng; Guohua Fan; Jie Huang; Ganjun Kang; Qing Geng; Bangchang Cheng; Wei Wang; Ping Dong
Journal:  Oncol Lett       Date:  2014-01-29       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.